Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

Seasonal Allergic Conjunctivitis Clinical Trial

Official title:
Evaluation of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to Its Components and Vehicle in an Allergen BioCube® in Subjects With Seasonal Allergic Conjunctivitis

Status Completed

Clinical Trial Summary

To evaluate the efficacy of Combo compared to its individual components and compared to vehicle in a population of subjects with seasonal allergic conjunctivitis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05591755
Study type	Interventional
Source	Bausch & Lomb Incorporated
Contact
Status	Completed
Phase	Phase 3
Start date	November 18, 2022
Completion date	August 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT01541904` - Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis	Phase 2
Completed	`NCT06212973` - A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients	Phase 3
Completed	`NCT01435460` - Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)	Phase 3
Completed	`NCT01342601` - Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents	N/A
Completed	`NCT01344083` - Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis	Phase 2
Completed	`NCT00133627` - Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis	Phase 4